Profile data is unavailable for this security.
About the company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
- Revenue in USD (TTM)2.59bn
- Net income in USD256.59m
- Incorporated1996
- Employees3.40k
- LocationBiomarin Pharmaceutical Inc770 Lindaro StreetSAN RAFAEL 94901United StatesUSA
- Phone+1 (415) 505-6700
- Fax+1 (415) 382-7889
- Websitehttps://www.biomarin.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc | 4.49bn | -1.26bn | 7.24bn | 9.30k | -- | 1.22 | -- | 1.61 | -2.55 | -2.55 | 9.09 | 12.02 | 0.3039 | 1.22 | 4.49 | 483,010.80 | -8.49 | -3.27 | -9.33 | -3.65 | 55.19 | 54.28 | -27.94 | -11.53 | 1.75 | 1.11 | 0.4886 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Intra-Cellular Therapies Inc | 564.53m | -84.30m | 7.89bn | 610.00 | -- | 6.89 | -- | 13.98 | -0.8629 | -0.8629 | 5.75 | 10.84 | 0.5551 | 1.33 | 4.67 | 925,452.40 | -8.29 | -38.27 | -9.47 | -42.77 | 92.72 | -- | -14.93 | -128.42 | 7.69 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Roivant Sciences Ltd | 158.30m | 4.74bn | 8.87bn | 845.00 | 2.15 | 1.63 | 1.91 | 56.06 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Catalent Inc | 4.38bn | -1.04bn | 10.95bn | 16.90k | -- | 3.01 | -- | 2.50 | -5.75 | -5.75 | 24.14 | 20.02 | 0.4268 | 4.88 | 3.01 | 259,230.80 | -10.16 | 0.0124 | -11.61 | 0.014 | 21.75 | 28.93 | -23.81 | 0.0278 | 1.93 | 0.6681 | 0.5765 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Incyte Corp | 3.86bn | 97.30m | 12.55bn | 2.52k | 184.29 | 4.17 | 68.05 | 3.25 | 0.3536 | 0.3536 | 17.18 | 15.64 | 0.7097 | 3.58 | 5.60 | 1,528,136.00 | 1.79 | 9.07 | 2.31 | 11.02 | 93.66 | 94.97 | 2.52 | 13.68 | 1.84 | -- | 0.0108 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Biomarin Pharmaceutical Inc | 2.59bn | 256.59m | 13.54bn | 3.40k | 53.63 | 2.56 | 37.32 | 5.23 | 1.33 | 1.33 | 13.28 | 27.77 | 0.3798 | 0.4778 | 3.98 | 761,069.70 | 3.76 | 0.7116 | 4.29 | 0.8079 | 80.07 | 76.30 | 9.91 | 2.05 | 1.95 | -- | 0.1708 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Viatris Inc | 15.24bn | -646.50m | 14.20bn | 38.00k | -- | 0.7275 | 6.59 | 0.932 | -0.5433 | -0.5433 | 12.68 | 16.36 | 0.3242 | 2.30 | 5.25 | 401,031.60 | -1.38 | 0.0887 | -1.62 | 0.1061 | 42.78 | 40.29 | -4.24 | 0.2891 | 1.02 | 2.48 | 0.4668 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Royalty Pharma plc | 2.24bn | 673.24m | 16.74bn | 89.00 | 18.76 | 1.96 | 19.94 | 7.48 | 1.50 | 1.50 | 3.74 | 14.42 | 0.1287 | -- | 76.10 | 25,141,870.00 | 5.92 | 9.57 | 7.77 | 12.42 | -- | -- | 46.02 | 67.80 | -- | -- | 0.4381 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 30 Jun 2024 | 18.79m | 9.87% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 18.55m | 9.75% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 17.86m | 9.38% |
| Dodge & Coxas of 30 Jun 2024 | 13.93m | 7.32% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 9.69m | 5.09% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 9.64m | 5.06% |
| Viking Global Investors LPas of 30 Jun 2024 | 7.06m | 3.71% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 4.56m | 2.39% |
| Columbia Management Investment Advisers LLCas of 30 Jun 2024 | 3.89m | 2.04% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 3.62m | 1.90% |
